Share This Article:

Predictability and Management of OARs Toxicity in Patients with Prostate Cancer Treated with High-Dose Radiotherapy

Abstract Full-Text HTML Download Download as PDF (Size:246KB) PP. 1452-1458
DOI: 10.4236/jct.2013.410174    3,147 Downloads   4,221 Views  

ABSTRACT

Aim: To evaluate the predictability of toxicity analyzing the dose-volume histograms (DVHs) and to verify the effectiveness of preventive measures limiting side toxicity considering the evolution of the radiation techniques for prostate cancer treatment. Materials and Methods: 208 patients with localized prostate cancer were treated with exclusive radiotherapy until 73.8 Gy (group A) or 79.2 Gy (group B) with the dose escalation technique. Preventive measures to minimize the side effects were recommended in group B. Results: The assessment of genitourinary toxicity was similar while gastrointestinal toxicity was better in group B. Valuating the treatment plans, we found that most of the patients developing toxicity had “borderline” DVHs. Conclusion: Our analysis led to the establishment of a protocol for the management of patients with “border-line” DVH.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

V. Ravo, D. Borrelli, S. Falivene, R. Franco, M. Muto, A. Argenone, V. Borzillo, F. Cammarota and P. Muto, "Predictability and Management of OARs Toxicity in Patients with Prostate Cancer Treated with High-Dose Radiotherapy," Journal of Cancer Therapy, Vol. 4 No. 10, 2013, pp. 1452-1458. doi: 10.4236/jct.2013.410174.

References

[1] M. M. Bismar and F. A. Sinicrope, “Radiation Enteritis,” Current Gastroenterology Reports, Vol. 4, No. 5, 2002, pp. 361-365. http://dx.doi.org/10.1007/s11894-002-0005-3
[2] K. Leiper and A. I. Morris, “Treatment of Radiation Proctitis,” Clinical Oncology (Royal College of Radiologists), Vol. 19, No. 9, 2007, pp. 724-729. http://dx.doi.org/10.1016/j.clon.2007.07.008
[3] E. H. Huang, A. Pollack, L. Levy, G. Starkschall, L. Dong, I. Rosen and D. A. Kuban, “Late Rectal Toxicity: Dose-Volume Effects of Conformal Radiotherapy for Prostate Cancer,” International Journal of Radiation Oncology, Biology, Physics, Vol. 54, No. 5, 2002, pp. 1314-1321.
http://dx.doi.org/10.1016/S0360-3016(02)03742-2
[4] R. Miralbell, D. Taussky, O. Rinaldi, A. Lomax, S. Canales, L. Escude, P. Nouet, O. Ozsoy and M. Rouzaud, “Influence of Rectal Volume Changes during Radiotherapy for Prostate Cancer: A Predictive Model for Mild-To-Moderate Late Rectal Toxicity,” International Journal of Radiation Oncology, Biology, Physics, Vol. 57, No. 5, 2003, pp. 1280-1284. http://dx.doi.org/10.1016/S0360-3016(03)00749-1
[5] S. T. Peeters, W. D. Heemsbergen, W. L. van Putten, A. Slot, H. Tabak, J. W. Mens, J. V. Lebesque and P. C. Koper, “Acute and Late Complications after Radiotherapy for Prostate Cancer: Results of a Multicenter Randomized Trial Comparing 68 Gy to 78 Gy,” International Journal of Radiation Oncology, Biology, Physics, Vol. 61, No. 4, 2005, pp. 1019-1034. http://dx.doi.org/10.1016/ j.ijrobp.2004.07.715
[6] J. J. Nuyttens, S. Milito, P. F. Rust, A. T. Turrisi, “DoseVolume Relationship for Acute Side Effects during High Dose Conformal Radiotherapy for Prostate Cancer,” Radiotherapy & Oncology, Vol. 64, No. 2, 2002, pp. 209-214. http://dx.doi.org/10.1016/S0167-8140(02)00185-8
[7] C. Fiorino, V. Vavassori, G. Sanguineti, C. Bianchi, G. M. Cattaneo, A. Piazzolla, C. Cozzarini, “Rectum Contouring Variability in Patients Treated for Prostate Cancer: Impact on Rectum Dose-Volume Histograms and Normal Tissue Complication Probability,” Radiotherapy & Oncology, Vol. 63, No. 3, 2002, pp. 249-255. http://dx.doi.org/10.1016/S0167-8140(01)00469-8
[8] J. J. Tuech, V. Chaudron, V. Thoma, J. C. Ollier, V. Tassetti, D. Duval and J. F. Rodier, “Prevention of Radiation Enteritis by Intrapelvic Breast Prosthesis,” European Journal of Surgical Oncology, Vol. 30, No. 8, 2004, pp. 900-904. http://dx.doi.org/10.1016/j.ejso.2004.06.012
[9] A. L. Zietman, M. L. Desilvio, J. D. Slater, C. J. Rossi Jr., D. W. Miller, J. A. Adams, W. U. Shipley, “Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate: A Randomized Controlled Trial,” JAMA, Vol. 294, No. 10, 2005, pp. 1233-1239. http://dx.doi.org/10.1001/jama.294.10.1233
[10] D. P. Dearnaley, M. R. Sydes, J. D. Graham, E. G. Aird, D. Bottomley, R. A. Cowan, R. A. Huddart, C. C. Jose, J. H. Matthews, J. Millar, A. R. Moore, R. C. Morgan, J. M. Russell, C. D. Scrase, R. J. Stephens, I. Syndikus, M. K. Parmar and RT01 Collaborators “Escalated-Dose versus Standard-Dose Conformal Radiotherapy in Prostate Cancer: First Results from the MRC RT01 Randomised Controlled Trial,” The Lancet Oncology, Vol. 8, No. 6, 2007, pp. 475-487. http://dx.doi.org/10.1016/S1470-2045(07)70143-2
[11] I. Syndikus, R. C. Morgan, M. R. Sydes, J. D. Graham, and D. P. Dearnaley, “Late Gastrointestinal Toxicity after Doseescalated Conformal Radiotherapy for Early Prostate Cancer: Results from the UK Medical Research Council RT01 trial (ISRCTN47772397),” International Journal of Radiation Oncology Biology Physics, Vol. 77, No. 3, 2010, pp. 773-783, http://dx.doi.org/10.1016/j.ijrobp.2009.05.052
[12] A. Al-Mamgani, W. L. van Putten, W. D. Heemsbergen, van G. J. Leenders, A. Slot, M. F. Dielwart, L. Incrocci and J. V. Lebesque, “Update of Dutch Multicenter Dose-Escalation Trial of Radiotherapy for Localized Prostate Cancer,” International Journal of Radiation Oncology, Biology, Physics, Vol. 72, No. 4, 2008, pp. 980-988. http://dx.doi.org/10.1016/j.ijrobp.2008.02.073
[13] A. Hille, N. T?ws, H. Schmidberger and C. F. Hess, “A Prospective Three-Dimensional Analysis about the Impact of Differences in the Clinical Target Volume in Prostate Cancer Irradiation on Normal-Tissue Exposure. A Potential for Increasing the Benefit/Risk Ratio,” Strahlentherapie und Onkologie, Vol. 181, No. 12, 2005, pp. 789-795. http://dx.doi.org/10.1007/s00066-005-1452-1
[14] R. Sauer, H. Becker, W. Hohenberger, C. Rodel, C. Wittekind, R. Fietkau, P. Martus, J. Tschmelitsch, E. Hager, C. F. Hess, J. H. Karstens, T. Liersch, H. Schmidberger and R. Raab, “German Rectal Cancer Study Group-Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer,” The New England Journal of Medicine, Vol. 351, No. 17, 2004, pp. 1731-1740. http://dx.doi.org/10.1056/ NEJMoa040694
[15] M. S. Litwin, R. D. Hays, A. Fink, P. A. Ganz, B. Leake, R. H. Brook, “The UCLA Prostate Cancer Index: Development, Reliability, and Validity of a Health-Related Quality of Life Measure,” Medical Care, Vol. 36, No. 7, 1998, pp. 1002-1012. http://dx.doi.org/10.1097/00005650-199807000-00007
[16] J. T. Wei, R. L. Dunn, M. S. Litwin, H. M. Sandler and M. G. Sanda, “Development and Validation of the Expanded Prostate Cancer Index Composite (EPIC) for Comprehensive Assessment of Health-Related Quality of Life in Men with Prostate Cancer,” Urology, Vol. 56, No. 6, 2000, pp. 899-905. http://dx.doi.org/10.1016/S0090-4295(00)00858-X
[17] S. T. Peeters, W. D. Heemsbergen, W. L. van Putten, A. Slot, H. Tabak, J. W. Mens, J. V. Lebesque and P. C. Koper, “Acute and Late Complications after Radiotherapy for Prostate Cancer: Results of a Multicenter Randomized Trial Comparing 68 Gy to 78 Gy,” International Journal of Radiation Oncology, Biology, Physics, Vol. 61, No. 4, 2005, pp. 1019-1034. http://dx.doi.org/10.1016/j.ijrobp. 2004.07.715
[18] S. T. Peeters, M. S. Hoogeman, W. D. Heemsbergen, A. A. Hart, P. C. Koper and J. V. Lebesque, “ Rectal Bleeding, Fecal Incontinence, and High Stool Frequency after Conformal Radiotherapy for Prostate Cancer: Normal Tissue Complication Probability Modeling,” International Journal of Radiation Oncology, Biology, Physics, Vol. 66, No. 1, 2006, pp. 11-19. http://dx.doi.org/10.1016/j.ijrobp. 2006.03.034
[19] M. J. Zelefsky, E. Aschkenasy, S. Kelsen and S. A. Leibel, “Tolerance and Early Outcome Results of Postprostatectomy Three-Dimensional Conformal Radiotherapy,” International Journal of Radiation Oncology, Biology, Physics, Vol. 39, No. 2, 1997, pp. 327-333. http://dx.doi.org/10.1016/S0360-3016 (97)00056-4
[20] C. L. Ohland and W. K. Macnaughton, “Probiotic Bacteria and Intestinal Epithelial Barrier Function,” Gastrointestinal and Liver Physiology, Vol. 298, No. 6, 2010, pp. G807-819. http://dx.doi.org/10. 1152/ajpgi.00243.2009
[21] R. Valdagni, T. Rancati, C. Fiorino, G. Fellin, A. Magli, M. Baccolini, C. Bianchi, E. Cagna, C. Greco, F. A. Mauro, A. F. Monti, F. Munoz, M. Stasi, P. Franzone and V. Vavassori, “Development of a Set of Nomograms to Predict Acute Lower Gastrointestinal Toxicity for Prostate Cancer 3D-CRT,” International Journal of Radiation Oncology, Biology, Physics, Vol. 71, No. 4, 2008 pp. 1065-1073. http://dx.doi.org/10.1016/j.ijrobp.2007.11.037
[22] V. Vavassori, C. Fiorino, T. Rancati, A. Magli, G. Fellin, M. Baccolini, C. Bianchi, E. Cagna, F. A. Mauro, A. F. Monti, F. Munoz, M. Stasi, P. Franzone and R. Valdagni “Predictors for Rectal and Intestinal Acute Toxicities during Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study,” International Journal of Radiation Oncology, Biology, Physics, Vol. 67, No. 5, 2007, pp. 1401-1410. http://dx.doi.org/10.1016/j.ijrobp.2006.10.040
[23] M. Roberfroid, G. R. Gibson, L. Hoyles, A. L. McCartney, R. Rastall, I. Rowland, D. Wolvers, B. Watzl, H. Szajewska, B. Stahl, F. Guarner, F. Respondek, K. Whelan, V. Coxam, M. J. Davicco, L. Léotoing, Y. Wittrant, N. M. Delzenne, P. D. Cani, A. M. Neyrinck and A. Meheust, “Prebiotic Effects: Metabolic and Health Benefits,” British Journal of Nutrition, Vol. 104, Suppl. 2, 2010, pp. S1-63.
http://dx.doi.org/10.1017/S0007114510003363

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.